Johnson & Johnson (JNJ.SG)
| Previous close | 135.30 |
| Open | 135.54 |
| Bid | 135.28 x N/A |
| Ask | 135.86 x N/A |
| Day's range | 135.40 - 135.62 |
| 52-week range | 132.92 - 161.10 |
| Volume | |
| Avg. volume | 500 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Johnson & Johnson Completes Acquisition of Shockwave Medical
NEW BRUNSWICK, N.J., May 31, 2024--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
- Globe Newswire
Johnson & Johnson MedTech gathers multi-disciplinary expert group to optimise lung cancer care and dialogue between patients and their healthcare team
ESTS - Congress site Palau de Congressos de Barcelona J&J symposium at the 32nd ESTS meeting in Barcelona, Spain J&J symposium: HCP and Patient Perspectives: Optimising Surgical Outcomes Through Collaboration Across the Treatment Continuum A recent European survey revealed that 80 percent of thoracic surgeons declared to follow the Enhanced Recovery After Surgery (ERAS) protocol, focussed on improving peri-operative lung cancer care,1 simultaneously, patients appear to continue experiencing conf
- PR Newswire
Sarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
